HENGRUI PHARMA (01276.HK): Three drugs win clinical trial approval
- R&D spending on SHR-2005 reached about RMB 56.60 million, with no comparable approved product.
- Adebrelimab is approved for first-line extensive-stage small cell lung cancer and for neoadjuvant and adjuvant treatment of operable NSCLC.
NewTimeSpace News: On 26 October 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276.HK) said three units received clinical trial approval from China's drug regulator for SHR-2005 injection, SHR-1501 for injection and adebrelimab injection. The approval covers SHR-2005 with SHR-1501, with or without adebrelimab and BCG, in bladder cancer, with applications filed on 7 May 2026.
SHR-2005, an in-house bladder cancer drug, has no comparable approved product; R&D spending was about RMB 56.60 million. SHR-1501 is an in-house IL-15 fusion protein; the US-approved comparator Anktiva had 2025 global sales of about USD 113 million, and R&D spending of RMB 129.50 million. Adebrelimab, a humanised anti-PD-L1 antibody, is approved for first-line extensive-stage small cell lung cancer and for neoadjuvant and adjuvant treatment of operable NSCLC, with R&D spending of RMB 1,370.30 million. All three still need trials and approval before launch.
- HENGRUI PHARMA (01276.HK): Rezvilutamide Tablets Win Clinical Trial Approval for Prostate Cancer Phase III Study
- HENGRUI PHARMA (01276.HK): SHR-3201 wins trial approval for AD
- HENGRUI PHARMA (01276.HK): Two Drugs Win Clinical Trial Approval in China
- HENGRUI PHARMA (01276.HK): SHR-4595 Gets Clinical Trial Approval in China
- HENGRUI PHARMA (01276.HK): Makes A-Share Repurchase of 335,000 Shares for RMB 14,503,550
